AMCAP™:
A Smarter Way to Cap mRNA

Evolving the enzymatic
mRNA manufacturing

AMCAP is Anemocyte’s proprietary, patent-pending one-pot technology for mRNA synthesis a smarter, faster way to combine transcription and capping in a single reaction.

Unlike standard two-step methods or matching the Co-trascriptional method, AMCAPdelivers efficiency, flexibility, and high-quality results with fewer steps and lower costs.

AMCAP One Pot
AMCAP processing

The Power of One Reaction

By merging transcription and capping into one seamless process, AMCAP™ enables rapid synthesis of 5’ CAP-1 mRNA with excellent yield, purity, and expression performance.
Its unique design reduces process time and downstream operations, while maintaining superior mRNA integrity.

AMCAP™ technology delivers a significant higher level of Cap1 structure on the 5′ endof the mRNA than the standard two step enzymatic method. Capping efficinecy and protein expression are comparable to method based on co-transcriptional capping.

Key advantages:

Flexible, Scalable, Proven

AMCAP™ is designed for flexibility – compatible with a wide range of commercially available reagents and adaptable to specific research goals: yield maximization, capping optimization, or enhanced protein expression.

AMCAP™ represents the next evolution in mRNA manufacturing.
It has been developed by Anemocyte, a Biotech Manufacturing Organization (BMO) with over 25 years of experience in innovative medicine in the field of Cell and Gene Therapy and nucleic acid.

Choose how you bring AMCAP™ technology into your workflow.

Join the enzymatic capping evolution of mRNA synthesis: faster, simpler, smarter.

1. Off-the-shelf mRNA products

Ready-to-use, high-performance mRNA for research and preclinical applications.
Engineered for superior transfection efficiency and robust protein expression.

2. AMCAP™ IVT Kit

A complete solution for in vitro transcription and capping – enabling seamless integration of AMCAP™ technology directly in your lab.

Discover AMCAP™

Join the enzymatic capping evolution of mRNA synthesis faster simpler smarter.

Visit shop.anemocyte.com to explore our AMCAP™ solutions.

Anemocyte S.r.l. Single Shareholder Private Limited-Liability Company
Via R. Lepetit, 34 21040 Gerenzano (VA) Italy | Ph: +39 02 99372311 – Fax: +39 02 99372313 | Anemocyte Inc. 1221 Brickell Avenue, Suite 1160 Miami FL 33131

VAT number: 12914940155 | Share capital € 530.000,00 fully paid | R.E.A. 276961